Abbott India vs Pfizer India: Which Stock Should You Track

Abbott India MCap Rs 58,933 Cr, PE 37.97x, ROE 32.51%, D/E 0.04, Div 2.37%. Pfizer India MCap Rs 22,431 Cr, PE 30.51x, ROE 17.19%, D/E 0.02, Div 1.53%.

Abbott India vs Pfizer India is a comparison investors look up when evaluating listed Indian subsidiaries of global MNC pharmaceutical companies. Abbott India is the Indian subsidiary of Abbott Laboratories (US), with a dominant position in branded prescription drugs across gastroenterology, metabolics, women’s health and thyroid segments. Pfizer India is the Indian subsidiary of Pfizer Inc (US), known for its cardiovascular, pain management and hospital products portfolio in India.

This Abbott India vs Pfizer India article covers reach and market position, key products, latest declared results and stock valuation. The Abbott India vs Pfizer India data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Abbott India vs Pfizer India: Reach and Market Position

On the Abbott India side of the Abbott India vs Pfizer India comparison, Abbott India operates a large field force promoting its branded prescription products to doctors across India. It has a dominant position in Thyronorm (levothyroxine) and a large gastroenterology portfolio. Market capitalisation is Rs 58,933 Cr.

Click Here – Get Free Investment Predictions

On the Pfizer India side of the Abbott India vs Pfizer India comparison, Pfizer India markets prescription drugs in cardiovascular, anti-infective and pain management segments through its doctor-focused field force. Market capitalisation is Rs 22,431 Cr.

Abbott India vs Pfizer India: Key Products and Business Mix

In the Abbott India vs Pfizer India product comparison, Abbott India offers: Abbott India earns from branded prescription drugs including Thyronorm (thyroid), Cremaffin (gastro), Duphaston (women’s health), Udiliv (liver) and others. EPS is Rs 730.36. P/E is 37.97x, ROE 32.51 percent, D/E 0.04. Dividend yield is 2.37 percent.

For Pfizer India in this Abbott India vs Pfizer India breakdown: Pfizer India earns from Cardace (cardiovascular), Dolonex (pain), Magnex and antibiotic ranges. EPS is Rs 160.70. P/E is 30.51x, ROE 17.19 percent, D/E 0.02. Dividend yield is 1.53 percent.

Abbott India vs Pfizer India: Latest Results

The Abbott India vs Pfizer India results for Abbott India: Abbott India has a market cap of Rs 58,933 Cr and P/E of 37.97x. ROE is 32.51 percent — one of the highest in the MNC pharma India segment. Near-zero debt and consistent high dividend. Abbott is approximately 2.6 times larger than Pfizer India by market cap.

The Abbott India vs Pfizer India results for Pfizer India: Pfizer India has a market cap of Rs 22,431 Cr and P/E of 30.51x. ROE is 17.19 percent, lower than Abbott India. Near-zero debt and a consistent dividend of 1.53 percent yield. Pfizer India trades at a lower P/E with a lower ROE.

Compare Abbott India and Pfizer India Fundamentals on the Univest Screener

Abbott India vs Pfizer India: Stock and Valuation

The Abbott India vs Pfizer India stock comparison uses the latest available market data from Groww. Investors tracking Abbott India vs Pfizer India should verify current prices on NSE or BSE before trading.

Abbott India vs Pfizer India at current valuations: Abbott trades at Rs 58,933 Cr market cap, P/E 37.97x, ROE 32.51 percent. Pfizer trades at Rs 22,431 Cr market cap, P/E 30.51x, ROE 17.19 percent. Abbott commands a premium P/E reflecting its dominant branded franchise and higher ROE. Both are near-zero debt businesses.

Abbott India vs Pfizer India: Quick Comparison Table

The Abbott India vs Pfizer India comparison table below summarises the key metrics covered in this article side by side.

Parameter	Abbott India	Pfizer India
Sector	MNC pharma India (gastro, thyroid, women’s health)	MNC pharma India (cardiovascular, pain, anti-infective)
Market Cap	Rs 58,933 Cr	Rs 22,431 Cr
P/E Ratio	37.97x	30.51x
ROE	32.51%	17.19%
Debt to Equity	0.04	0.02
Dividend Yield	2.37%	1.53%
Parent	Abbott Laboratories (USA)	Pfizer Inc (USA)

Conclusion

The Abbott India vs Pfizer India comparison above covers the key data points on reach, products, results and valuation. Abbott India vs Pfizer India covers two well-run MNC pharma India subsidiaries with consistent cash generation, low debt and regular dividends. Abbott India has a higher ROE and dominant branded products, particularly in thyroid care. Pfizer India is smaller with a cardiovascular and anti-infective focus. Both are dependent on the parent company’s product pipeline decisions and royalty arrangements. Investors should review branded market share, field force productivity, drug pricing controls, and dividend policy before taking a view. Consult a SEBI-registered advisor.

Download the Univest iOS App or Univest Android App to track Abbott India and Pfizer India live price and get daily stock recommendations.

SEBI Research Analyst Registration No. INH000013776

Frequently Asked Questions

What drugs does Abbott India sell?

Ans. Abbott India sells Thyronorm (levothyroxine for thyroid), Cremaffin (laxative), Duphaston (women’s health), Udiliv (liver), and a wide range of prescription drugs in gastroenterology, metabolics and neurology.

What is Abbott India’s ROE?

Ans. Abbott India has an ROE of approximately 32.51 percent — one of the highest among listed MNC pharma companies in India.

Does Abbott India pay dividends?

Ans. Yes. Abbott India pays a dividend yield of approximately 2.37 percent with a history of consistent annual dividends.

What does Pfizer India sell?

Ans. Pfizer India sells cardiovascular drugs including Cardace, analgesics, anti-infectives and hospital products. Pfizer India’s portfolio is narrower than Abbott India’s in terms of therapy breadth.

Are Abbott India and Pfizer India listed in India?

Ans. Yes. Both Abbott India and Pfizer India are listed on BSE and NSE as Indian companies. They are subsidiaries of their respective global parent companies.

Is there a risk of delisting for MNC pharma subsidiaries?

Ans. Historically, some MNC pharma subsidiaries have been delisted when the parent company increased its stake above SEBI’s mandatory public float threshold. Investors should track promoter shareholding and any open offer announcements.

Which is larger by market cap, Abbott India or Pfizer India?

Ans. Abbott India is larger at Rs 58,933 Cr versus Pfizer India at Rs 22,431 Cr.